Live attenuated vaccines are highly effective for acute viral diseases but face safety and efficacy challenges for chronic infections like HIV.
Caution advised for live attenuated HIV vaccines; leaves open alternative platforms for chronic infections.
Live attenuated vaccines against human viral diseases have been amongst the most successful cost effective interventions in medical history. Smallpox was declared eradicated in 1980; poliomyelitis is nearing global eradication and measles has been controlled in most parts of the world. Vaccines function well for acute diseases such as these but chronic infections such as HIV are more challenging for reasons of both likely safety and probable efficacy. The derivation of the vaccines used has in general not been purely rational except in the sense that it has involved careful clinical trials of candidates and subsequent careful follow up in clinical use; the identification of the candidates is reviewed.
No takes yet. Share an insight, caveat, or question.
Philip D. Minor (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: